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INTRODUCTION
Foot deformities are the most common musculoskeletal prob-
lem in children with cerebral palsy (CP).1 The most common 
deformity is equinus foot. Spastic equinovarus foot character-
ized by limited ankle dorsiflexion with forefoot inversion is also 
common in children with CP, particularly hemiplegic type.1 
Dynamic foot deformities in ambulatory children with CP can 
lead to inadequate initial heel contact with resultant instability 
in stance phase and poor foot clearance in swing phase. In ad-
dition, the abnormal foot pressure distribution while walking 
can lead to local pain and callus formation.
Over the last decade, Botulinum toxin type A (BoNT-A) injec-
tion for spastic muscles has been widely used in children with 
spastic CP. In recent systematic reviews, BoNT-A injection has 
been recommended as a therapeutic choice in the manage-
ment of dynamic equinus foot in children with CP.2,3 However, 
most previous studies used subjective measures to assess the 
effects of the injection, such as the modified Ashworth scale 
(MAS)4 and the observational gait scale score, which may have 
biased the results.5-9 
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Three-dimensional computerized gait analysis is recognized 
as an objective and reliable tool to measure changes in ambula-
tion after therapeutic intervention. Previous studies using com-
puterized gait analysis after BoNT-A injection for equinus foot 
in children with CP revealed several significant changes in 
ankle kinematic data and kinetic data.8,10-15 Although used as a 
gold standard for planning and assessing the outcome of cor-
rective musculoskeletal surgery in CP patients, the computer-
ized gait analysis system has limited ability to reveal significant 
changes in foot deformities in the frontal plane such as valgus 
and varus deformities after therapeutic intervention.16,17 
Static foot pressure analysis has been utilized in children 
with CP as a clinical tool for assessing the changes in foot con-
tact pattern in the standing position after BoNT-A injection for 
dynamic equinus.18,19 However, the dynamic foot deformity that 
occurs during walking may not be adequately assessed using 
a static technique. Dynamic foot pressure measurement via a 
computerized insole sensory system is recognized as a reliable 
tool for assessing dynamic changes of foot pressure distribu-
tion while walking.20,21 Thus, dynamic foot pressure measure-
ments have been successfully obtained in children with CP to 
assess pressure distribution while walking.22-24 Previous studies 
demonstrated significant changes in foot pressure distribution 
using dynamic foot scans after therapeutic intervention for 
valgus or varus deformities.23,24 
For equinovarus foot, the tibialis posterior (TP) is the rec-
ommended targeted muscle along with the calf muscles for 
BoNT-A injection in patients with stroke and CP.5,6,25-27 To the 
best of our knowledge, the effects of BoNT-A injection into the 
TP and calf muscles have not yet been reported in children 
with CP. 
Therefore, the aim of this study was to investigate the effects 
of BoNT-A injection for dynamic equinovarus foot in children 
with CP by using computerized gait analyses and foot scans. 
MATERIALS AND METHODS
This was a prospective intervention study conducted in a uni-
versity teaching hospital between October 2012 and May 2014.
Participants
Children with spastic CP who met the following inclusion and 
exclusion criteria were recruited for this study. 
Inclusion criteria were as follows: 1) able to walk indepen-
dently without assistance [Gross Motor Function Classifica-
tion System (GMFCS) level I–II], 2) dynamic equinovarus foot 
leading to foot inversion with heel elevation during walking, 3) 
MAS ≥2 at ankle plantarflexors with knee extension, 4) ankle 
range of motion (ROM) with knee extension over neutral po-
sition, 5) age >3 years, and 6) able to understand and follow 
commands. 
Exclusion criteria were as follows: 1) chemodenervation ther-
apy within 6 months, 2) previous selective rhizotomy or ortho-
pedic surgery, and 3) history of allergy to the toxin.
Ethical approval was granted by the Institutional Review 
Board and Ethics Committee of Severance Hospital (#4-2012-
0381). Study subjects and their guardians provided written in-
formed consent. 
In total, 25 ambulatory children with spastic CP (17 hemi-
plegic, 8 diplegic; 19 girls, 6 boys), aged 3 to 15 years (mean, 
7.64±2.91 years), whose GMFCS level was I or II (GMFCS level 
I/II: 21/4) participated in this study (Table 1).
Both hemiplegic and diplegic children had unilateral spas-
tic equinovarus foot. Accordingly, BoNT-A was injected into 
25 lower legs for spastic equinovarus foot.
 
Intervention
Local anesthetic (lidocaine cream) was topically applied at 
the injection site 1 hour before BoNT-A injection. Reconstitut-
ed vials containing 200 units of BoNT-A (Neuronox®, Medytox 
Inc., Cheongju, Korea) with 4 mL of normal saline to provide 
a solution containing 50 units/mL were prepared for injec-
tion. BoNT-A was injected at two points at the medial and lat-
eral heads of the gastrocnemius (GCM) under the guidance of 
ultrasonography (US) with the child in prone position. The 
dose ranged from 2.5 to 5.0 units/kg depending on the severity 
of spasticity (mean±SD=3.86±0.68 U/kg). In addition, BoNT-A 
was injected into one or two sites in the TP muscle under US 
guidance using an anterior approach at the upper third point of 
the tibia, with doses ranging from 0.9 to 2.8 units/kg (mean± 
SD=1.73±0.54 U/kg).28 All children participated for 30 minutes 
in a standardized physiotherapy program, which included 
stretching and strengthening of the ankle plantarflexor and gait 
training following 4 months after the injections. No electrical 
stimulation or casting was applied.
Assessments
Clinical measures of spasticity
The muscle tone of the ankle plantarflexor was assessed using 
the MAS and modified Tardieu scale (MTS) in both knee flex-
ion and extension. The MAS is a 6-point rating scale from 0 to 
Table 1. Characteristics of the Participants
Characteristic
Sex (F/M), n 19/6 
Age (mean±SD), yrs (range) 7.64±2.91 (3–15)
GMFCS level (I/II), n 21/4 
Type of cerebral palsy (diplegia/hemiplegia), n 8/17 
Injection site (right/left), n 12/13
Injected dose (mean±SD), U/kg
Gastrocnemius muscle 3.86±0.68 (2.5–5.0)
Tibialis posterior 1.73±0.54 (0.9–2.8) 
SD, standard deviation; GMFCS, Gross Motor Functional Classification Sys-
tem. 
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4 that is used to gauge muscle tone. For statistical analysis, an 
MAS grade of 1 (+) was converted to 2. Likewise, MAS grades 
of 2, 3, and 4 were converted to 3, 4, and 5, respectively. 
As for the MTS,29 two levels of the angle of ankle dorsiflex-
ion were measured after slow and fast stretches of the ankle 
joint, referring to R2 and R1 angles respectively. R1 was defined 
as the point in the ROM where a catch was first felt during a 
quick stretch of the ankle plantarflexor, while R2 was defined 
as the total passive ROM of ankle dorsiflexion. R2-R1 repre-
sents the dynamic components of spasticity.30 The ankle joint 
angles for R1 and R2 were measured via manual goniometry 
using the “neutral-null” method (dorsiflexion angle over neu-
tral position was counted in positive degrees, and plantarflex-
ion over neutral position was counted in negative degrees). 
 
Gait analysis using a computerized gait system
Gait analysis was performed using a computerized gait sys-
tem (VICON MX-T10 Motion Analysis System, Oxford Metrics 
Inc., Oxford, UK) to measure kinematic data (angles of pelvis, 
hip, knee, and ankle joints) and kinetic data (moments of knee 
flexor and ankle plantar-flexor) during the gait cycle. Subjects 
were instrumented with passive reflective markers consistent 
with the VICON Plug-in-Gait model for gait analysis. A trained 
investigator who had 20 years of clinical experience in gait 
analysis placed 16 reflective markers on the posterior superior 
iliac spine, the anterior superior iliac spine, the mid points of 
the lateral femur, the lateral knee joint axis, and the midpoints 
of the lateral tibia, the lateral malleolus, the heel, and the dor-
sal foot between metatarsal heads 2 and 3. Six digital videos 
were recorded simultaneously from the front, rear, and side 
while the child walked barefoot at a comfortable walking speed 
on an 8-m pathway. Data from five trials at a self-selected 
walking speed were collected for each subject. Each patient 
was told to look straight ahead and walk as naturally as possi-
ble. All data were captured in the gait analysis laboratory. 
Force-plates (AMTI OR 6-5, Advanced Mechanical Technolo-
gy, Newton, MA, USA) under the path recorded ground reac-
tion forces during the walking trials with a 1000-Hz sampling 
frequency, and joint moments were expressed as internal mo-
ments to counter the ground reaction force. Data collection 
continued until the subject achieved at least three “clean” 
force-plate strikes. 
Foot pressure measurement 
Dynamic foot pressure measurements using the F-scan sys-
tem (Tekscan Inc., South Boston, MA, USA) was used to cap-
ture the plantar pressure distribution during walking. The 
pressure was recorded at 50 Hz using a pressure sensitive in-
sole consisting of a 0.15-mm thick sensor with an embedded 
gridwork of 960 pressure-sensing cells, evenly distributed at 
0.5-cm (0.2-in) intervals. After the pressure reading data were 
saved, pedobarograph data were exported in ASCII using F-
scan Research software V6.70 (Tekscan Inc., South Boston, 
MA, USA). A minimum of five captures per foot were subse-
quently recorded, and three representative footprints in the 
middle of the test were selected. The mean values were calcu-
lated for all of the following parameters.23 
Foot contact pattern 
The foot contact pattern, obtained by foot scan, is a useful tool 
for assessing changes after therapeutic interventions for foot 
deformities.23 For the overall contact pattern and specific ar-
eas of the foot, the most common technique for foot segmen-
tation was described by Bowen, et al.31 in 1998 and has subse-
quently been used by several authors.23,32 This technique 
consists of rotating the pedobarograph footprint until the pro-
jection of the long axis of the foot is vertically aligned. The foot 
is then divided into five regions: hind-foot, lateral midfoot, 
medial midfoot, lateral forefoot, and medial forefoot. The cen-
ter of pressure index (COPI) was calculated with the method 
described by Oeffinger, et al.33 as the “area of the lateral column 
divided by the area of the medial column.” The COPI in a nor-
mal foot has a value close to one. 
Pressure time integrals (PTIs)
According to the description from a previous study, the foot 
was divided into five sections: medial forefoot, lateral forefoot, 
medial midfoot, lateral midfoot, and heel.23 The area under 
the pressure/time curve shows the total pressure achieved by 
each section of the foot; this total pressure was the “impulse” 
for this study. The relative impulse was defined as the per-
centage of impulse exerted on each section from the total im-
pulses of the five sections. The relative impulse distributed 
under the medial column of the foot was the sum of the rela-
tive impulses of the medial forefoot and midfoot. Likewise, 
the relative impulse under the lateral column was the sum of 
the relative impulses of the lateral forefoot and midfoot. As 
proposed by Chang, et al.32 and in our previous study,23 we de-
fined the coronal index as the relative impulse in the medial 
column minus the relative impulse in the lateral column. The 
coronal index in a normal foot has a value close to zero. The 
COPI and coronal index reflect the asymmetry of the medial 
and lateral columns of the foot. The dynamic foot pressure in-
dex (DFPI), which was proposed by Bennett, et al.22 as a useful 
index for tracking the changes after injection for dynamic 
equinus, was calculated as the ratio of the impulse of the heel 
to the impulse of the heel and forefoot. 
Statistical analysis
SPSS version 20 (SPSS Inc., Chicago, IL, USA) was used for 
statistical analysis. A one-way repeated-measures ANOVA 
was used to compare the changes between baseline data and 
the data at 1 month and 4 months after injection. Bonferroni 
post hoc tests were applied to further analyze the time factor. 
The level of significance was set as p<0.05. 
499http://dx.doi.org/10.3349/ymj.2016.57.2.496
Ja Young Choi, et al.
RESULTS 
Clinical evaluations 
The tone of the ankle joint measured via MAS and MTS showed 
statistically significant changes. Post hoc analysis demonstrat-
ed a significant reduction in spasticity at both 1 and 4 months 
after injection when compared to baseline data. These find-
ings indicated that the effects of BoNT-A injection on tone re-
duction were still present at 4 months after injection. Howev-
er, the statistically significant differences in MAS and MTS 
with knee flexion between 1 and 4 months after injection ob-
served via post hoc analysis indicated that the effects lessened 
as the pharmacologic effects of BoNT-A wore off (Table 2). R2-
R1 angles of MTS were significantly improved at 1 month after 
injection compared to baseline, though only in the knee ex-
tension position. The GCM is two-joint muscle; thus, the sig-
nificant improvements in the R2-R1 angle of MTS were appar-
ent only with knee extension, not in the knee flexion position. 
Gait analysis using a computerized gait system
Kinematic data of the ankle joint revealed significant changes 
after injection (Fig. 1). Post hoc analysis revealed significant 
improvements in the ankle angle at initial contact, maximal 
ankle dorsiflexion in stance phase, and mean ankle dorsiflex-
ion during stance phases along with significant reduction of 
maximal ankle plantarflexion at push-off at both 1 and 4 
months after injection compared to baseline. Maximal and 
mean ankle dorsiflexion angles in swing phase were signifi-
cantly improved at 4 months after injection compared to base-
line. 
Regarding foot progression, there were no significant chang-
es in mean and maximal internal rotation during the entire 
gait cycle. 
At the proximal joints, there were significant changes in pel-
vis rotation at initial contact, maximal hip extension in stance 
phase, and maximal knee extension in mid-stance phase. 
However, after post hoc analysis, only changes in pelvic exter-
nal rotation at initial contact at 4 months after injection and 
maximal hip extension in stance phase at 1 and 4 months af-
ter injection were significant compared to baseline data (Table 
3). The kinetic data showed significant changes in ankle pow-
er generation, specifically between baseline and 4 months af-
ter infection, on post hoc analysis (Table 4). 
Foot pressure measurement 
Foot contact pattern 
The total foot contact area, contact length, and contact width 
of the hindfoot showed statistically significant changes. Post 
hoc analysis demonstrated a significant increase in these pa-
rameters 1 month after injection compared to the data before 
injection. There were also statistically significant changes in 
COPI after injection with post hoc analysis, demonstrating 
significant improvement of COPI at 1 and 4 months after in-
jection compared to baseline data. However, there were no 
significant changes in COPI at 4 months after injection when 
compared to data at 1 month after injection (Table 5).
Plantar pressure distributions
There were statistically significant changes in the relative im-
pulse of the lateral forefoot, medial and lateral midfoot, heel 
section of the foot, and DFPI and coronal index. Post hoc 
analysis demonstrated a significant reduction in the relative 
impulses of the lateral forefoot and lateral midfoot and a sig-
nificant increase in the coronal index at both 1 and 4 months 
after injection, as well as significant enhancement of the rela-
tive impulses of the medial midfoot, heel, and DFPI at 1 
month after injection, compared to baseline. Post hoc analysis 
between 1 and 4 months after injection revealed a significant 
enhancement in the pressure time integrals of the lateral fore-
Table 2. Changes in Clinical Assessment 
Parameters Before injection 1 month after injection 4 months after injection ANOVA p value
MAS
Ankle with knee flexion 2.88 (±0.67) 2.16 (±0.55)* 2.44 (±0.65)*† <0.001
Ankle with knee extension 3.24 (±0.44) 2.20 (±0.71)* 2.48 (±0.65)* <0.001
R1 of MTS (degrees) 
Ankle with knee flexion -5.20 (±9.63) 3.28 (±9.86)* -1.16 (±9.33)*† <0.001
Ankle with knee extension -16.48 (±8.95) -7.56 (±9.20)* -9.68 (±8.59)* <0.001
R2 of MTS (degrees) 
Ankle with knee flexion 14.04 (±9.67) 19.44 (±9.24)* 17.80 (±10.29)* 0.001
Ankle with knee extension 4.60 (±6.76) 8.48 (±7.84)* 7.52 (±7.64)* 0.001
R2-R1 of MTS (degrees) 
Ankle with knee flexion 19.24 (±8.60) 16.16 (±5.23) 18.96 (±7.36)† 0.042
Ankle with knee extension 21.08 (±7.01) 16.04 (±5.84)* 17.20 (±7.08) 0.003
MAS, modified Ashworth scale; MTS, modified Tardieu scale.
Data are presented as mean (±standard deviation).
*Post hoc analysis, compared with baseline, p<0.05, †Post hoc analysis, compared with after 1 month data, p<0.05.   
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foot and midfoot as well as a significant reduction in the coro-
nal index at 4 months after injection. 
DISCUSSION 
Dynamic foot deformities are the most common musculo-
skeletal problem in children with spastic CP.1 BoNT-A injec-
tion is widely used as a therapeutic intervention for dynamic 
foot deformities in patients with CP. A number of studies have 
demonstrated the benefits of BoNT-A injection for dynamic 
equinus foot in patients with CP.1,2,13-15,19,34,35 However, previous 
studies on the effects of such an injection for dynamic equin-
ovarus foot have rarely addressed children with CP. For dynam-
ic equinovarus foot, TP and calf muscles are the target muscles 
for BoNT-A injection.36 In patients with stroke, a number of 
studies revealed the significant benefits of the BoNT-A injec-
tion for dynamic equinovarus.5,6,26,37 Based on previous double 
blind randomized placebo controlled studies, BoNT-A injec-
tion into the TP and calf muscles had significant benefits on 
tone reduction, gait velocity and walking ability in adults with 
stroke or focal hypertonia due to various diseases.6,26,37,38 How-
ever, those studies did not investigate kinematic or kinetic 
changes using computerized gait analysis or dynamic foot pres-
sure measurements via F-scan. To the best of our knowledge, 
there has only been one study to date using computerized gait 
analysis to assess the effects of BoNT-A injection for dynamic 
equinovarus.7 In that study, BoNT-A was injected into the so-
leus muscles in eight patients with stroke and into the TP and 
flexor hallucis longus muscles in half of them; after injection, 
there a certain degree of improvement in ankle kinematics such 
as ankle position at initial contact and maximal ankle dorsiflex-
ion during gait, with results comparable to tibial neurotomy.7 
In children with CP with dynamic equinus foot, a number 
of studies have previously demonstrated significant improve-
ments in ankle kinematic parameters10-13,15,39 and kinetic data10,12 
using computerized gait analysis after BoNT-A injection into 
the calf muscles. The significant improvements in ankle kine-
matic data shown in our study were due to the reduction of 
ankle plantarflexor tone after injection, which contributed to 
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significant improvement in ankle dorsiflexion during gait. 
These finding are in line with the results of previous studies 
on the effects of BoNT-A injection for dynamic equinus. Previ-
ous studies have investigated changes in ankle kinetic param-
eters after injection into calf muscles for dynamic equinus10,12,34 
and shown that ankle power generation, which represents 
push-off ability, was improved after injection, although not to 
a significant level.12,34 Boyd, et al.10 demonstrated significant 
improvement after injection in the ankle power quotient, which 
is calculated as the ratio between power absorption and pow-
er generation.
Our study revealed significant improvements in ankle pow-
er generation at 4 months after injection compared to base-
line data. The changes of ankle kinetic and kinematic data pro-
vide evidence of improved gait pattern and power generation 
at the ankle after BoNT-A injection. Overall, these findings are 
compatible with those of previous studies on the effects of 
BoNT-A injection into calf muscles for dynamic equinus foot. 
For computerized gait analysis, we adopted the Plug-in-Gait 
model, a conventional marker set for the VICON motion cap-
ture system. This model is unable to measure frontal-plane 
ankle motion, which is why our study could not demonstrate 
relevant improvements in foot inversion. However, maximal 
and mean internal rotation were unchanged, which implies 
that BoNT-A did not alter foot adduction, which is in turn in-
fluenced by the TP.40 
On the other hand, the secondary effects of BoNT-A injec-
tion for equinus foot on the proximal joints are inconsistent in 
the literature. After injection into the calf muscles for equinus 
foot, several studies have demonstrated significant changes in 
knee kinematic data,12,13 while others have not shown signifi-
cant effects on the knee joint.13,39 In addition, the secondary 
effects of BoNT-A injection on the hip joint have been rarely 
investigated in children with CP. Only one study has demon-
Table 3. Changes in Kinematic Parameters of Gait Analysis 
Parameters Before injection 1 month after injection 4 months after injection ANOVA p value
Pelvis (degrees)
Pelvic tilt at initial contact 15.83 (±4.38) 14.55 (±5.00) 15.26 (±4.25) 0.107
Mean pelvic tilt in stance phase 17.92 (±4.77) 16.57 (±4.87) 17.51 (±4.49) 0.143
Pelvic rotation at initial contact 2.54 (±7.29) 0.87 (±5.37) -1.02 (±7.96)* 0.008
Mean pelvic rotation in stance phase -3.28 (±4.32) -3.92 (±4.08) -3.70 (±4.85) 0.673
Max pelvic rotation during gait cycle -11.90 (±5.26) -12.03 (±5.02) -10.43 (±7.08) 0.279
Pelvic rotation ROM during gait cycle 17.60 (±5.86) 16.12 (±6.58) 16.51 (±8.01) 0.462
Hip (degrees)
Hip flexion at initial contact 45.80 (±6.83) 43.85 (±6.76) 43.99 (±6.71) 0.081
Maximal hip extension in terminal stance phase 3.24 (±7.61) 0.95 (±5.86)* -0.36 (±8.18)* 0.006
Hip adduction at initial contact -1.76 (±5.09) -0.65 (±3.99) -1.52 (±4.84) 0.270
Mean hip adduction in stance phase 1.81 (±5.56) 1.26 (±4.29) 0.65 (±5.32) 0.234
Hip rotation at initial contact -7.87 (±9.76) -4.89 (±9.97) -5.58 (±9.03) 0.170
Mean hip rotation in stance phase -3.22 (±7.68) -1.83 (±7.66) -2.83 (±7.69) 0.224
Knee (degrees)
Knee angle at initial contact 29.37 (±7.75) 28.42 (±8.00) 27.42 (±9.72) 0.224
Maximal knee extension angle in mid-stance 11.54 (±9.88) 9.17 (±6.40) 8.22 (±8.76) 0.044
Maximal knee flexion angle in swing phase 66.71 (±9.79) 67.37 (±8.72) 65.65 (±8.54) 0.363
Ankle (degrees)
Ankle angle at initial contact -7.05 (±5.52) -5.37 (±4.89)* -5.22 (±4.59)* 0.002
Maximal dorsiflexion angle in stance phase 9.43 (±7.19) 12.76 (±6.16)* 12.32 (±6.14)* 0.002
Maximal plantarflexion angle at push-off -16.59 (±9.54) -11.70 (±6.39)* -12.61 (±6.35)* 0.004
Mean dorsiflexion angle in stance phase 0.32 (±6.18) 3.30 (±4.70)* 2.86 (±4.10)* 0.001
Maximal dorsiflexion angle in swing phase -5.43 (±7.27) -3.59 (±5.45) -2.83 (±5.12)* 0.009
Mean dorsiflexion angle in swing phase -8.84 (±7.62) -6.24 (±5.43) -6.17 (±5.43)* 0.005
Total ankle ROM 26.02 (±7.00) 24.46 (±7.03) 24.93 (±6.41) 0.514
Foot progress (degrees) 
Maximal internal rotation 10.79 (±9.29) 10.06 (±9.61) 8.87 (±8.46) 0.342
Mean internal rotation during entire gait cycle 3.00 (±8.45) 2.37 (±8.58) 1.02 (±8.50) 0.068
Data are presented as mean (±standard deviation). Positive values indicate pelvic anterior tilt, pelvic internal rotation, hip flexion, hip adduction, hip internal ro-
tation, knee flexion, and ankle dorsiflexion, while negative values indicate pelvic external rotation, hip extension, hip abduction, hip external rotation, and ankle 
plantarflexion. 
*Post hoc analysis, compared with baseline, p<0.05.
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strated a significant secondary effect on the hip joint, specifi-
cally an increase in hip flexion at initial contact and hip excur-
sion after injection into the calf muscles, characterized by a 
more flexed hip during the entire gait cycle.12 The authors of 
that study assumed that the reduced ankle power caused by the 
BoNT-A injection led to the need for more hip extensor power, 
which worsened hip flexion during gait. On the contrary, our 
study revealed that maximal hip extension during the termi-
nal stance phase increased after BoNT-A injection. Therefore, 
further studies are needed to delineate the effects of BoNT-A 
injection for dynamic foot deformities on the knee and hip 
joints. 
Foot deformities result in an abnormal distribution of load 
on the plantar surface of the foot. The F-scan insole system is 
a reliable and reproducible method of recording pressure dis-
tribution on the foot during walking.20,21,41 Therefore, foot pres-
sure has also been assessed in children with CP as an outcome 
measure after therapeutic interventions for foot deformi-
ties.22-24 According a previous study, BoNT-A injection into the 
calf muscles for dynamic equinus foot in children with CP led 
to significant improvements in the entire plantar surface area 
and peak pressure values in the hindfoot.18 Another study also 
demonstrated significant changes in dynamic foot pressure 
distribution in the stance phase after BoNT-A injection into 
the GCM muscles for dynamic equinus with and without cast-
ing in children with CP. In that study, the reduction of ankle 
plantarflexor tone and increase of ankle joint ROM with the 
therapeutic intervention led to significant improvement of 
heel contact, which contributed to significant increases in to-
tal contact area and DFPI.22 The results of our study also re-
vealed significant improvements in total contract area, con-
tact length, and contact width of the hind foot and also of the 
relative impulse over the heel and DFPI, which are compati-
ble with the findings of previous studies. 
Table 4. Changes in Kinetic Parameters of Gait Analysis
Parameters Before injection 1 month after injection 4 months after injection ANOVA p value
Knee flexor
Maximal moment in stance phase (N-m/kg) 0.26 (±0.15) 0.25 (±0.10) 0.25 (±0.12) 0.923
Mean moment in stance phase (N-m/kg) -0.13 (±0.15) -0.13 (±0.14) -0.14 (±0.09) 0.859
Ankle plantarflexor 
Maximal moment in loading response (N-m/kg) 0.87 (±0.35) 0.78 (±0.37) 0.77 (±0.43) 0.289
Maximal moment in terminal stance (N-m/kg) 0.81 (±0.19) 0.84 (±0.18) 0.90 (±0.23) 0.083
Mean moment in stance phase (N-m/kg) 0.51 (±0.16) 0.52 (±0.15) 0.52 (±0.16) 0.765
Ankle power generation (watt/kg) 1.74 (±0.95) 1.99 (±0.72) 2.38 (±1.12)* 0.007
Data are presented as mean (±standard deviation). 
*Post hoc analysis, compared with baseline data, p<0.05. 
Table 5. Changes in Dynamic Foot Pressure Distributions 
Parameters Before injection 1 month after injection 4 months after injection ANOVA p value
Foot contact pattern
Total contact area (cm2) 50.79 (±14.09) 57.79 (±15.94)* 54.70 (±16.81) 0.005
Contact length (cm) 14.98 (±2.48) 15.90 (±2.94)* 15.68 (±2.84) 0.008
Contact width  
Forefoot (cm) 6.18 (±0.81) 6.33 (±0.78) 6.21 (±0.89) 0.186
Midfoot (cm) 2.73 (±0.71) 2.71 (±0.90) 2.63 (±0.85) 0.755
Hindfoot (cm) 3.19 (±1.40) 3.93 (±1.27)* 3.81 (±1.20) 0.009
Center of pressure index 1.67 (±0.47) 1.23 (±0.28)* 1.29 (±0.30)* <0.001
Relative impulse of PTIs  
Medial forefoot (%) 20.28 (±9.72) 21.41 (±9.21) 21.65 (±10.28) 0.494
Lateral forefoot (%) 27.09 (±7.80) 18.99 (±7.07)* 21.48 (±7.61)*† <0.001
Medial midfoot (%) 8.03 (±5.38) 12.71 (±3.44)* 11.89 (±6.37) 0.006
Lateral midfoot (%) 28.27 (±13.26) 21.78 (±10.31)* 24.60 (±9.59)*† <0.001
Heel (%) 16.33 (±10.38) 25.11 (±12.19)* 20.39 (±14.25) <0.001
Coronal index -27.05 (±21.69) -6.65 (±17.31)* -12.54 (±15.50)*† <0.001
DFPI (%) 26.39 (±15.90) 38.85 (±18.03)* 32.56 (±20.22) 0.001
Center of pressure index, (area in lateral column)/(area in medial column); Coronal index, (relative impulses in medial forefoot and medial midfoot)-(relative im-
pulses in lateral forefoot and lateral midfoot); PTI, pressure time integral; DFPI, dynamic foot pressure index [heel impulse/(heel impulse+forefoot impulse)×100].
Data are presented as mean (±standard deviation). 
*Post hoc analysis, compared with baseline data, p<0.05, †Post hoc analysis, compared with after 1 month data, p<0.05.   
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On the contrary, few studies have shown changes in dy-
namic foot pressure distribution after therapeutic interven-
tion for equinovalgus or equinovarus deformities. According 
to a previous study,23 the parameters reflecting medial or lat-
eral weight-bearing such as the COPI and coronal index are 
useful for evaluating foot deformities and changes after thera-
peutic intervention in the frontal plane, such as in varus and 
valgus deformities. Our study found a significant reduction in 
COPI at 1 and 4 months after injection, which indicated that 
the varus foot contact pattern moved toward a more neutral 
foot position. The significant decrease in the relative impulse 
of the lateral forefoot and midfoot and significant increase of 
the medial midfoot and coronal index suggest improvement 
in foot pressure distribution after intervention as well. BoNT-
A injection into the TP led to a significant reduction of forefoot 
inversion, which contributed to an improvement in foot pres-
sure distribution during gait, although the posture of the foot, 
such as forefoot adduction, was not altered according to gait 
analysis. These findings suggest that dynamic pressure data 
are useful for tracking the changes in both the frontal and sag-
ittal planes of the ankle and foot after intervention. 
Although this is the first report investigating the effects of 
BoNT-A injection for dynamic equinovarus foot by using com-
puterized gait analysis and foot scans in children with CP, we 
acknowledge that our study had several limitations. First, our 
study lacked a control group, and further randomized control 
trials are needed to address this limitation. In addition, the 
age of our subjects ranged from 3 to 15 years. In children with 
CP, the most rapid improvements in gross motor function oc-
cur during the first 4 years of life and reach a plateau between 
5 and 6 years depending on their disability.42 The age of our 
study participants likely affected our results, as young children 
have greater potential for improvement. The extent of the limi-
tations in ROM and hypertonia at the ankle may also be con-
founding factors affecting the outcomes after BoNT-A injec-
tion. Further studies are needed with a larger sample size to 
delineate the best candidates for BoNT-A injection for dynamic 
equinovarus foot. BoNT-A injection is a reversible treatment; 
thus, repeat injections may be needed. In the present study, 
the follow-up was limited to 4 months after injection. There-
fore, the interval of repeat injections and the long-term effects 
of the injection were beyond the scope of this study. Further 
study is also needed to address this issue. The other limitation 
of our study was that MAS, which was the outcome measure-
ment of our study, has several limitations in terms of accuracy 
and reliability in the measurement of dynamic spasticity. In 
our study, ankle MAS was improved in both knee flexion and 
extension; however, the R2-R1 angle of MTS was improved 
only in the knee extension position. The GCM is a two-joint 
muscle; thus, the improvements in ankle spasticity with knee 
flexion may not be expected with BoNT-A injection into the 
GCM. Therefore, we think that the significant reduction of an-
kle spasticity after BoNT-A injection can ease the stretching of 
the ankle joint, and it may result in significant gains in ankle-
passive ROM for both knee flexion and extension. In addition, 
BoNT-A injection into the TP also seems to contribute to signif-
icant improvements in ankle ROM with knee flexion. 
In conclusion, our study suggested that BoNT-A injection 
into the TP and GCM had significant benefits in terms of gait 
parameters and dynamic foot pressure distribution. Further 
randomized control studies in larger groups of children are 
necessary to delineate the best candidates for injection in terms 
of age and the extent of limited ROM and tone.
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